Go Pro
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
Compare

CMRA vs. NAVB, PXMD, ADTX, GNCA, and ARDS

Should you buy Comera Life Sciences stock or one of its competitors? Comera Life Sciences's main competitors and comparable companies include Navidea Biopharmaceuticals (NAVB), PaxMedica (PXMD), Aditxt (ADTX), Genocea Biosciences (GNCA), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Comera Life Sciences Neutral

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Comera Life Sciences N/A N/A N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Comera Life Sciences Neutral

PaxMedica has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

4.9% of PaxMedica shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to Aditxt?

Comera Life Sciences (NASDAQ:CMRA) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Comera Life Sciences has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Given Comera Life Sciences' higher possible upside, equities research analysts clearly believe Comera Life Sciences is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Comera Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Comera Life Sciences has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Aditxt$14.34K0.39-$41.71M-$100.79 thousandN/A

15.5% of Aditxt shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Aditxt Neutral

Comera Life Sciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Comera Life Sciences' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

Summary

Comera Life Sciences beats Aditxt on 9 of the 12 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Comera Life Sciences Neutral

0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Comera Life Sciences has lower revenue, but higher earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Comera Life Sciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Comera Life Sciences N/A N/A N/A

Summary

Comera Life Sciences beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to Aridis Pharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Comera Life Sciences has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.66, suggesting that its stock price is 4,866% more volatile than the broader market.

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Comera Life Sciences. Comera Life Sciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Aridis Pharmaceuticals Neutral

Comera Life Sciences has higher revenue and earnings than Aridis Pharmaceuticals. Comera Life Sciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Comera Life Sciences on 5 of the 8 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3K$12.25B$7.26B$12.73B
Dividend YieldN/A2.59%2.53%8.86%
P/E Ratio0.00787.27273.2925.38
Price / SalesN/A753.78613.4597.56
Price / CashN/A94.8077.8252.26
Price / BookN/A12.3312.896.14
Net Income-$18M$2.82B$3.47B$349.01M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$8KN/AN/A2
ADTX
Aditxt
0.1708 of 5 stars		$0.01
+17.2%		N/A-100.0%$6K$14.34KN/A60
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel